CDXS — Codexis, Inc.

Summary of Codexis (CDXS) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $8.6 million for Q3 2025, down from $12.8 million in Q3 2024, primarily due to variability in customer manufacturing schedules and clinical trial progress.
• Product Gross Margin: Increased to 64% from 61% year-over-year, attributed to a shift towards more profitable products.
• R&D Expenses: Rose to $13.9 million from $11.5 million, driven by higher headcount and lab supply costs.
• SG&A Expenses: Decreased to $11.2 million from $13.6 million, reflecting lower employee-related costs and reduced legal expenses.
• Net Loss: $19.6 million or $0.22 per share, slightly improved from a net loss of $20.6 million or $0.29 per share in Q3 2024.
• Cash Position: $58.7 million at the end of Q3, excluding funds from the Merck agreement, which is expected to extend the runway through 2027.

2. Strategic Updates and Business Highlights

• Merck Agreement: A significant supply assurance agreement was signed, providing nondilutive cash and confidence in revenue projections.
• Facility Expansion: Codexis is set to lease a new facility for GMP-grade siRNA manufacturing, enhancing its capabilities in oligonucleotide manufacturing.
• ECO Synthesis Platform: The company has transitioned from one revenue-generating contract to 11, with 40 more in the pipeline, indicating strong commercial traction.
• Leadership Transition: Alison Moore will succeed Stephen Dilly as CEO, with a focus on leveraging her technical expertise to drive the company’s strategic initiatives.

3. Forward Guidance and Outlook

• Codexis expects to meet or slightly exceed the top end of its 2025 revenue guidance, with a significant portion of revenue from the Merck contract recognized in Q4 2025 and Q1 2026.
• The company anticipates a restructuring that could reduce its cash burn by approximately 25%, allowing for continued investment in growth areas.
• Specific guidance for 2026 will be provided in early 2026, but the company is optimistic about maintaining favorable margins due to existing products in clinical trials.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The drop in total revenues raises concerns about the impact of customer manufacturing schedules and the potential for continued variability.
• Shift in Strategy: The transition away from the small molecule biocatalysis business could lead to a temporary decline in service revenue as the company focuses on ligase and ECO Synthesis.
• Market Dynamics: There is pricing pressure in the enzyme development contracts, which may affect future revenue growth from the legacy business.
• Headcount Reductions: The decision to reduce headcount across various groups may impact operational efficiency and morale.

5. Notable Q&A Insights

• Partnership Strategy: Management confirmed that the leadership transition will not alter existing plans for partnerships, with ongoing discussions and contracts in progress.
• Customer Feedback: The performance of the ECO platform is reportedly meeting customer expectations, which could enhance future partner conversations.
• Upcoming TIDES EU Conference: The company is set to present data on the scaling of its technology, which could be pivotal for attracting new customers and partners in the siRNA therapeutic market.

Overall, Codexis is navigating a significant transition with a focus on expanding its oligonucleotide manufacturing capabilities while managing challenges related to revenue variability and strategic refocusing.